J Gynecol Oncol.
2024 Jan;35(1):e43. 10.3802/jgo.2024.35.e43.
Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Inha University Hospital, Inha University College of Medicine, Incheon, Korea
- 2Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea
- 3Department of Obstetrics and Gynecology, Kyung Hee University Medical Center, School of Medicine, Kyung Hee University, Seoul, Korea
- 4Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea
- 5Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea
- 6Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
- 7Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 8Department of Obstetrics and Gynecology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
- 9Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
- 10Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea
- KMID: 2564864
- DOI: http://doi.org/10.3802/jgo.2024.35.e43
Abstract
- Since the latest practice guidelines for ovarian cancer were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2021, many studies have examined the efficacy and safety of various treatments for epithelial ovarian cancer (EOC). Therefore, the need to develop recommendations for EOC treatments has been raised. This study searched the literature using 4 key items and the Population, Intervention, Comparison, and Outcome: the efficacy and safety of poly-ADP ribose polymerase inhibitors in newly diagnosed advanced EOC; the efficacy and safety of intraperitoneal plus intravenous chemotherapy in optimally debulked advanced EOC; the efficacy and safety of secondary cytoreductive surgery in platinumsensitive recurrent ovarian cancer; and the efficacy and safety of the addition of bevacizumab to platinum-based chemotherapy in first platinum-sensitive recurrent EOC patients who received prior bevacizumab. The evidence for these recommendations, according to each key question, was evaluated using a systematic review and meta-analysis. The committee of ovarian cancer of the KSGO developed updated guidelines for treatments of EOC.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines
- Role of lymphadenectomy for ovarian cancer
- Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines
- Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines
- Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
